The MPP granted a sub-licence to Beximco to produce Bristol-Myers Squibb’s new hepatitis C drug daclatasvir. The name of originator brand is Daclinza.
With the recognition, Beximco becomes the first ever Bangladeshi company to achieve the unique feat, said a released issued yesterday.
daclatasvir is an antiviral that can cure all major genotypes of the HCV virus. The drug received regulatory approval in Europe in August 2014 and was included in the new WHO Model List of Essential Medicines in April 2015.
In November 2015, MPP announced a licence and technology transfer agreement with Bristol-Myers Squibb (BMS) to increase access to DCV in low- and middle-income countries.
On the inclusion into the MPP’s network of generic medicine producers, Beximco Pharma Managing Director Nazmul Hassan, also lawmaker, said: “We are glad to be a part of this global network as the first Bangladeshi company.”
“We believe our competitive cost of production will help improve access to this new and highly effective hepatitis C treatment for patients in many low- and middle-income countries.”
Leave a Comment